Skip to main content
 

Press Releases

September 8, 2020
First allogeneic CAR-T cell therapy with PD-1 deleted by CRISPR genome editing cleared for Phase 1 clinical trials Upon initiation of the ANTLER Phase 1 clinical trial, CB-010 will be Caribou’s first clinical-stage product candidate
May 11, 2020

BERKELEY, Calif.--Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of Clinical Development. In this newly created position, Dr. Thomas will serve as Caribou’s clinical leader and oversee the advancement of the Company’s first allogeneic CAR-T cell therapy candidate, expected to start clinical trials later this year.

In the News

Harnessing Type I CRISPR–Cas systems for genome engineering in human cells

November 19, 2019

Using a FokI fusion design, we show that Type I CRISPR-Cas systems can be expressed, reconstituted, and faithfully trafficked to the nucleus for genome engineering in human cells.

This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer

March 16, 2018

In a fashionable fitted blazer, Rachel Haurwitz looks the part of a polished executive when she meets me in the largest conference room of her company, Caribou Biosciences. She’s sharp and tactical as she speaks, even though it was just a few years ago that Haurwitz traded her lab coat for a tailored suit and stepped up to lead a staff of 46 as Caribou’s CEO.

About Us

Pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products. Learn more. 

Contact Us

For media and investor inquiries and general information, click here.

Follow Us

Connect with us on Twitter for the latest news and updates. Click here.

Media Contact

Greg Kelley
Senior Vice President
Feinstein Kean Healthcare
(404) 836-2302
gregory.kelley@fkhealth.com